Navigation Links
Innovative method to starve tumors
Date:2/11/2009

This release is available in French.

Montreal, February 11th, 2009 - The development of cancerous tumours is highly dependent on the nutrients the tumours receive through the blood. The team of Dr. Janusz Rak, of the Research Institute of the McGill University Health Centre (MUHC) at the Montreal Children's Hospital, including Dr. Khalid Al-Nedawi and Brian Meehan, has just discovered a new mechanism that tumours use to stimulate the growth of the blood vessels that feed them. The researchers have also proposed a new way to control this process, which may translate into future therapies. These findings were published this week in the Proceedings of the National Academy of Sciences (PNAS).

An innovative method

According to the researchers, tumour cells can release "bubbles" called microvesicles, which allow the tumours to communicate with the endothelial cells of blood vessels and stimulate changes in their behaviour. The microvesicles are armed with specific cancer proteins as they leave the tumour. When they are taken up by endothelial cells, the specific cancer proteins that they carry can trigger mechanisms that promote the abnormal formation of new blood vessels. The vessels then grow towards the tumour and supply it with the nutrients it requires to grow.

"We had already demonstrated the existence of these vesicles as well as their importance in the communication process between cancer cells and their environment. But this new discovery is much more targeted and represents a new direction in terms of therapy," said a delighted Dr. Rak.

to starve tumors

In fact, a family of molecules derived from annexin V seems to effectively fight this process and ultimately may help "starve" the tumour. "The molecule we used is effective both in vitro and in vivo. It prevents the formation of new blood vessels in mice with cancer and therefore strongly inhibits tumour growth," explained Dr. Rak.

Called Diannexin, this molecule acts to block the in vitro fusion of vesicles and endothelial cells. In mice with cancer, Diannexin works to slow blood vessel growth towards the tumour, resulting in anti-cancer effects. This finding is particularly important considering the treatment was applied in isolation without additional chemotherapy. If combined with other agents, this new way of treating cancer may be even more potent.

Diannexin is currently being developed as an antithrombotic medication. It would therefore be possible to use it safely for different types of pathologies.


'/>"/>

Contact: Isabelle Kling
isabelle.kling@muhc.mcgill.ca
514-843-1560
McGill University Health Centre
Source:Eurekalert

Related medicine news :

1. Patient-Centered Medical Homes Can Improve Care, Reduce Costs; Independence Blue Cross Medical Executive Discusses Innovative PA Program With Nations Health Care Policy Makers
2. Congressional Leaders Can Look to Indiana for Innovative Approach to Health IT in Economic Stimulus Package
3. E-VERIFILE.COM, Inc. Selects Medium Blue Search Engine Marketing to Highlight Its Innovative Screening and Hiring Solutions with Search Engine Optimization and Online PR
4. First-Ever Over-the-Counter Dual Action Iron Supplement Available at Major Retail Outlets in the United States; Bifera is a New, Innovative Dual Iron Supplement Now on the Market
5. The Amazing Heat Pack: The Most Innovative First Aid Solution Since the Band-Aid
6. TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS
7. Teleconference on Monday, January 19, Announcing New, Innovative Dual Iron Supplement Now Available Over the Counter
8. The Leukemia & Lymphoma Society and The University of Kansas Cancer Center Announce Innovative Partnership to Accelerate Drug Development
9. WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder
10. California Woman Receives Most Advanced, Non-Invasive Upper Extremity Prosthetic Solution: Bionic i-LIMB Hand and Innovative Interface System Increase Amputee's Functionality and Confidence
11. Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Dr. Ronald E. Hawkins, vice president ... of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean ... Dr. Bell comes to Liberty from the Ohio University Heritage College of Osteopathic ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec ... it’s not if you will be attacked, but when.” However, he and many others ... health care. , Improvements in auditing and monitoring have taken security in health care ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... ... to The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite ... Medical District with easy access to Highway 121. , As the practice has grown, ...
(Date:2/24/2017)... ... , ... With ProGlass Prism users now have the ability to simulate prism ... position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, anchor ... Prism users are given the tools and effects to generate a fractal prismatic ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition of the "Menopause Drugs ... ... Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks ... What are the key drugs marketed for ... Menopause market? What are the unit prices and annual ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
Breaking Medicine Technology: